Find Academic Supervisors

Professor Maria Craig is a distinguished academic and researcher at the University of New South Wales, Faculty of Medicine & Health, specializing in childhood diabetes research. She holds a prominent position as a Professor with extensive contributions to the field of pediatric endocrinology and diabetes, particularly focusing on type 1 diabetes in children. Professor Craig's educational background includes: MB BS from the University of Melbourne MMedSc(ClinEpid) from the University of Newcastle PhD from the University of Sydney FRACP (Fellow of the Royal Australasian College of Physicians) Professor Craig's research primarily focuses on childhood diabetes, with special emphasis on prediction and prevention of type 1 diabetes. She has a significant interest in the association between viruses and type 1 diabetes, collaborating with the Virology Research Group at Prince of Wales Hospital (POWH). Together with Professor Bill Rawlinson, she leads the viral theme for the multicentre ENDIA study (endia.org.au). As principal investigator for the CoRD trial, she is conducting a world-first phase 1 study using autologous cord blood for prevention of type 1 diabetes in children with islet autoimmunity. Additionally, she serves as principal investigator for the Australasian Diabetes Data Network (ADDN). Her research portfolio also encompasses the epidemiology of various forms of childhood diabetes (type 1, type 2, cystic fibrosis related diabetes and monogenic diabetes) and diabetes complications, in collaboration with Professor Kim Donaghue at the Children's Hospital at Westmead. Professor Craig's extensive publication record, including over 361 journal articles, demonstrates her leadership in advancing our understanding of childhood diabetes. Her recent work shows increasing focus on early detection methods, risk prediction models, technological interventions for diabetes management, and the complex interplay between viral infections and autoimmune diabetes development. She has been instrumental in developing clinical practice guidelines through her role as co-editor of the International Society for Pediatric and Adolescent Diabetes (ISPAD) guidelines. Professor Craig has received numerous prestigious awards recognizing her contributions to pediatric endocrinology and diabetes research: Australian Paediatric Endocrine Group Young Investigator's Award (1997) Asia Pacific Paediatric Endocrine Society Clinical Teaching Award (2008) Lifetime Honorary Member, Caring and Living as Neighbours (2013) Australian Diabetes Society Jeff Flack Diabetes Data Award (2019) Australian Paediatric Endocrine Group Norman Wettenhall Award for Research and Innovation (2019) Throughout her career, Professor Craig has demonstrated exceptional leadership in professional societies, having served as former president/treasurer of the Australasian Paediatric Endocrine Group (APEG) and currently as Scientific Convenor of the Asia Pacific Paediatric Endocrine Society Fellows school. Her work with the ENDIA study and Australasian Diabetes Data Network represents significant collaborative research efforts involving multiple institutions across Australia and internationally. Her principal investigator roles for major studies indicate substantial research funding support. Professor Craig leads several important research initiatives including the ENDIA study, the CoRD trial, and the Australasian Diabetes Data Network. These programs involve multidisciplinary teams of researchers, clinicians, and support staff working collaboratively to advance understanding and treatment of childhood diabetes. Her work at the intersection of virology and diabetes represents a unique and innovative approach to understanding the environmental triggers of type 1 diabetes.

• Childhood Diabetes
• Type 1 Diabetes
• Virology and Diabetes
• +4 more

Laura Elo serves as Professor of Computational Medicine and Head of the Medical Bioinformatics Centre at the University of Turku, Finland. She concurrently holds the position of Research Director at Turku Bioscience Centre and acts as InFLAMES Flagship Contact, driving interdisciplinary biomedical research initiatives. Her academic foundation includes a PhD in Applied Mathematics (2007) and Adjunct Professorship in Biomathematics (2011), establishing her quantitative expertise before transitioning into biomedical applications. Her research program focuses on transforming molecular and clinical datasets through statistical modeling and advanced machine learning . Key thrusts include robust computational tools for proteome/epigenome analysis, AI-driven digital health diagnostics, and computational systems immunology for immune-mediated diseases. This work directly addresses challenges in reproducibility and scalability of high-throughput biotechnology data. Analysis of her recent publications reveals dominant themes in type 1 diabetes biomarker discovery , multi-omics integration , and immune system modeling , with strong emphasis on clinical translation through collaborations with experimental and medical teams. Her scientific recognition includes: JDRF Career Development Award Professor Elo actively trains MSc/PhD students and postdoctoral fellows while leading major research initiatives including ERC grants. Her teaching portfolio spans Bioinformatics Journal Club, AI in Diagnostics, and Systems Biology courses. The Elo Lab (https://elolab.utu.fi) operates as a hub for computational biomedicine, developing open-source tools like CellRomeR while maintaining close ties with Turku Bioscience Centre's experimental facilities for validating computational predictions in immunology and metabolic disease contexts.

• Computational Biomedicine
• Medical Bioinformatics
• Data Science
• +7 more

Yao Qin is an Assistant Professor in the Department of Electrical and Computer Engineering at the University of California, Santa Barbara (UCSB), with dual affiliation in the Department of Computer Science. She concurrently serves as Co-Director of the REAL AI Initiative at UCSB and holds a Senior Research Scientist position at Google DeepMind, where she contributes to the Gemini Multimodal project. Her academic credentials include a PhD in Computer Science and Engineering from the University of California, San Diego (advised by Prof. Garrison W. Cottrell) and a BS in Electrical Engineering from Dalian University of Technology. During her doctoral studies, she completed internships with pioneering researchers Geoffrey Hinton and Ian Goodfellow. Dr. Qin's research program centers on machine learning robustness, with emphasis on adversarial robustness, out-of-distribution generalization, and fairness. She develops reliable AI systems specifically for healthcare applications, with diabetes management as a primary focus. Her lab explores critical themes including AI safety in multimodal models and diabetes-specific AI solutions, particularly exercise metabolism modeling and glycemic effect prediction. Recent publications reveal a strong trajectory in robust machine learning with cross-domain applications. Her work consistently bridges theoretical robustness concepts with practical healthcare implementations, particularly in diabetes care. Key publication venues include CVPR, ICML, NeurIPS, and ICLR, with notable contributions to out-of-distribution detection, adversarial transfer learning, and multimodal AI safety. Her distinguished recognition includes: EECS Rising Star at MIT (2021) UCSB Regents' Junior Faculty Fellowship Award Helmsley Charitable Trust award for Type 1 diabetes research UCSB Faculty Research Grant American Diabetes Association Abstract Award (ADA-2025) Dr. Qin actively mentors four PhD students—Mehak Dhaliwal, Andong Hua, Kenan Tang, and Youngseok Yoon—on projects spanning LLMs for diabetes, multimodal robustness, and generative time-series modeling. Her research is funded by the Helmsley Charitable Trust and UCSB, with recent grants supporting exercise-specific AID algorithms for diabetes management. As Co-Director of the REAL AI Initiative, she leads a research ecosystem focused on developing reliable artificial intelligence. Current lab activities include organizing workshops at NeurIPS-2024 (AdvML-Frontiers and AIM-FM) and developing next-generation diabetes management tools through collaborations with medical institutions.

• Machine Learning
• Adversarial Robustness
• Out-of-Distribution Generalization
• +5 more

Dr. Steven G. Clarke is a Distinguished Professor at UCLA Department of Chemistry & Biochemistry and director of research at the Molecular Biology Institute . His work bridges protein chemistry , methylation biology , and aging research through studies of spontaneous protein damage and its repair mechanisms. Education: BA in Chemistry and Zoology, Pomona College (magna cum laude, Phi Beta Kappa) PhD in Biochemistry and Molecular Biology, Harvard University (NSF Fellow) Postdoctoral Fellowship at UC Berkeley (Miller Fellow) Dr. Clarke's research focuses on protein isoaspartyl repair via PCMT1/PIMT enzymes , ribosomal protein methylation in Saccharomyces cerevisiae , and PRMT family characterization including PRMT7 and PRMT9. His lab combines biochemical assays , genetic models , and structural analysis to investigate aging mechanisms and disease implications. Recent publications highlight: COQ5 structure-function analysis in coenzyme Q biosynthesis PCMTD1 ubiquitin ligase interactions PRMT7 substrate specificity in histone H2B Protein isoaspartyl impacts on T cell function in lupus Novel PRMT inhibitors for cancer therapy Methionine addiction in osteosarcoma malignancy Major scientific awards: American Chemical Society Ralph F. Hirschmann Award in Peptide Chemistry NIH MERIT Award Ellison Medical Foundation Senior Scholar Award William C. Rose Award, ASBMB UCLA Distinguished Teaching Award (Eby Award winner) Current lab members include PhD candidates Eric Pang (UCSB) and Sining "Cindy" Wang (UCLA), while undergraduates Celeste Medina-Seymoure , Elizabeth Oroudjeva , Olivia Pacheco , and Jasmine Winter contribute to ongoing proteostasis studies. Collaborations with Profs. Jose Rodriguez and Catherine Clarke demonstrate interdisciplinary research approaches.

• Biochemistry
• Systems Biology
• Biological Regulation
• +8 more

Björn Pasternak is a Research Professor leading the Pharmacoepidemiology group at the Department of Medicine, Solna, Karolinska Institutet. His team specializes in large-scale registry studies focused on adverse drug effects, with research programs in pediatric pharmacoepidemiology, safety of diabetes medications, and rapid assessment of drug safety concerns. The group leverages high-quality epidemiological methods to inform evidence-based clinical decisions. Pasternak's research interests span pharmacoepidemiology, drug safety, diabetes outcomes, cardiovascular risk, and perinatal health. His work utilizes nationwide registries to evaluate real-world drug effects, socioeconomic disparities in treatment, and long-term outcomes of chronic therapies. Key focuses include GLP-1 receptor agonists, SGLT2 inhibitors, antibiotic use in pregnancy, and opioid safety. Recent publications demonstrate strong emphasis on Scandinavian cohort studies of diabetes medications (GLP-1 agonists, SGLT2 inhibitors) and their associations with thyroid cancer, liver events, intestinal obstruction, and cardiovascular/renal outcomes. Other trends include perinatal pharmacovigilance (antibiotics, acid-suppressive drugs) and neurodegenerative risks in athletes.

• Pharmacoepidemiology
• Drug Safety
• Diabetes Mellitus
• +3 more

Harri Lähdesmäki is an Associate Professor (tenured) at the Department of Computer Science, Aalto University, where he leads the Computational Systems Biology research group. His work focuses on probabilistic machine learning and deep generative models with applications in biomedicine and molecular biology. Key Research Interests: Probabilistic machine learning, deep generative models, computational biology, bioinformatics, longitudinal data modeling Contact: harri.lahdesmaki@aalto.fi | Konemiehentie 2, 02150 Espoo, Finland His recent publications highlight advancements in: Gaussian process priors for scalable deep generative models Single-cell analysis of immune repertoires in leukemia and diabetes Probabilistic deconvolution methods for RNA-seq data Epigenetic analysis using hidden Markov and mixed models Transformer-based survival prediction and missing data handling Harri’s work integrates mechanistic modeling with Bayesian inference, particularly applied to immunology, cancer biology, and early disease prediction.

• Probabilistic Machine Learning
• Deep Generative Models
• Artificial Intelligence
• +4 more

Elaine M. Huang is an Associate Professor of Human-Computer Interaction at the Department of Informatics, University of Zurich, where she has served since 2010. She also leads the People and Computing Lab, focusing on the dynamic interplay between human practices and technological advancements. Her academic background includes: PhD in Computer Science, Georgia Institute of Technology (2006) Dr. Huang's research centers on human-computer interaction, examining the bidirectional relationship between technology and human practices. She is particularly known for her work on gender equality in technology, challenging assumptions about innate gender differences and investigating how AI systems may perpetuate biases. Her research also spans sustainable interaction design, mental health technologies, and chronic disease management, always emphasizing empirical data over intuition. Analysis of her recent publications (2023-2025) reveals a strong trajectory toward socially impactful HCI, with significant focus on health technologies (diabetes management, mental health), cultural sensitivity in design, and the ethical challenges of AI. Her methodology often involves field studies to understand real-world technology use, countering the industry's reliance on intuition. As head of the People and Computing Lab, Dr. Huang oversees a research group dedicated to designing and evaluating technologies that address complex human needs. The lab's work frequently involves co-design with diverse user communities to ensure relevance and inclusivity in technological solutions.

• Human-Computer Interaction
• Gender Equality in Technology
• AI and Society
• +3 more

KEMAL OZAN LÜLE is an Assistant Professor at Gaziantep University, Faculty of Medicine, Department of Internal Medicine , with an email contact at ozan@gantep.edu.tr . He holds an ORCID identifier and is registered in the YÖK Academic Information System. Education: Medical License from Dokuz Eylül University (2009–2016), Medical Specialization from Gaziantep University (2017–2021). Professional Experience: Specialist at Gaziantep Abdulkadir Yuksel State Hospital (2021–2024), General Practitioner at Arapgir Ali Özge State Hospital (2016–2017). Administrative Roles: Member of Measurement and Evaluation Board (2024), Internal Medicine Internship Education Coordinator (2024), English Medicine Assistant Coordinator (2024). His research focuses on Internal Medicine , with emphasis on Diabetes , Fatty Liver Disease , Neurocognitive Effects of diabetes treatments, Cancer Development linked to food preparation, Irritable Bowel Syndrome , and Adrenal Incidentaloma . Book Chapters: Development and Natural Course of Diabetic Fatty Liver Disease (2025), Effects of Pharmacological Agents on Neurological Functions (2023), Food Preparation Methods and Cancer (2023). He has co-authored multiple proceedings papers on topics including Temporal Arthritis , Lymphoma , Behçet’s Disease , and Fahr Syndrome , presented at national and international conferences.

• Internal Medicine
• Endocrinology
• Gastroenterology
• +6 more

Julia Lawton is Professor of Health & Social Science at the Usher Institute , University of Edinburgh, where she leads the Edinburgh Qualitative Health Research Group (EQual) . Her work focuses on improving healthcare delivery through qualitative research, particularly in chronic condition self-management and health inequalities. Education: PhD and BA in Social Anthropology from University of Cambridge Research Themes: Diabetes self-management, health technology adoption, inequities in healthcare access, process evaluations of complex interventions Key Projects: UNBIASED (diabetes technology disparities), REDUCE (diabetic foot ulcers), CL4P-CF (cystic fibrosis-related diabetes), AiDAPT (pregnancy diabetes management) Her recent publications highlight innovations in diabetes care, including closed-loop systems, structured education, and addressing disparities in technology access for underserved populations. She collaborates extensively with NHS entities and international institutions.

• Qualitative Health Research
• Diabetes Self-Management
• Health Inequalities
• +4 more

Jennica Zaro, PhD, serves as Associate Professor of Pharmacology and Pharmaceutical Sciences at the University of Southern California (USC) School of Pharmacy and Assistant Dean for Assessment in the Office of Graduate Education and Postdoctoral Studies. Previously, she held academic leadership roles at West Coast University School of Pharmacy and directed the Translational Research and Histology laboratories at USC Mann. Education: PhD in Pharmaceutical Sciences, University of Southern California BS, Stockton University Her pioneering research focuses on engineering recombinant fusion proteins for targeted drug delivery, particularly developing liver-specific insulin therapies for diabetes and pH-sensitive nanoconstructs for tumor targeting. This interdisciplinary work bridges protein engineering, nanomedicine, and translational pharmacology to create site-specific therapeutic systems with enhanced efficacy and reduced side effects. Analysis of her recent publications reveals a cohesive research trajectory centered on protein-drug conjugates, with significant contributions in pH-responsive delivery systems (2017-2018) and liver-targeted insulin analogs (2016-2018). Her work consistently appears in high-impact journals like Journal of Controlled Release and Biomaterials , demonstrating expertise in translating molecular designs into therapeutic applications. Scientific Awards: Most Innovative Award (2017, West Coast University) Advisor of the Year Award (2017, West Coast University, School of Pharmacy) Dr. Zaro has secured substantial research funding as Principal Investigator for NIH National Cancer Institute projects (2013-2016) and USC Ming Hsieh Institute grants (2014-2015), plus consultancy roles with Juvenile Diabetes Research Foundation (2016-2018). She actively shapes national research policy through service on NIH and UK Medical Research Council review panels and the American Foundation for Pharmaceutical Education Board of Grants. Her laboratory expertise includes the Translational Research and Histology core facilities at USC Mann, and she maintains active roles in professional organizations including the Controlled Release Society, American Association of Pharmaceutical Scientists, and American Association of Colleges of Pharmacy.

• Targeted Drug Delivery
• Recombinant Fusion Proteins
• Protein Drugs
• +4 more

Dr Virginia Hagger is a Senior Lecturer in Nursing at Deakin University's School of Nursing & Midwifery, part of the Faculty of Health and the Institute for Health Transformation. She specializes in diabetes education, self-management, and psychological wellbeing. Her research focuses on structured education programs, diabetes distress, and workforce development. She holds a PhD and Master of Public Health from Deakin University. Dr Hagger has led numerous national and international studies, including interventions targeting diabetes distress, insulin therapy barriers, and telehealth support. She is affiliated with the Quality and Patient Safety (QPS) Strategic Research Centre and the Australian Centre for Behavioural Research in Diabetes . Awards include the 2019 Alfred Deakin Medal and 2017 Vice-Chancellor's Award for Teaching Excellence. Her teaching spans undergraduate and postgraduate nursing, including units on diabetes pathophysiology and psychosocial contexts. Current doctoral students focus on diabetes distress, social support in Ethiopia, and autonomy in insulin management. Over 30 peer-reviewed articles and grants (e.g., MRFF-funded HypoPAST and LISTEN trials) underscore her contributions to diabetes care innovation and workforce training.

• Diabetes self-management
• Structured diabetes education
• Diabetes distress and psychological wellbeing
• +3 more

Maria J. Redondo is a Professor at Baylor College of Medicine and leads the Maria J. Redondo Lab at Texas Children’s Hospital, focusing on Type 1 Diabetes across four core areas: Genetics for prediction models and trial candidate selection Heterogeneity in diabetes pathogenesis Prevention through clinical trials Atypical Diabetes and Racial/Ethnic Influences Research Trends: Her recent articles emphasize genetic risk modeling, BMI correlations in pediatric diabetes, and HLA studies. The work integrates autoimmunity , metabolic research , and epidemiological analysis . Scientific Awards: Elected to the Society for Pediatric Research (2014) JDRF Early Career Development Award (2002) JDRF Postdoctoral Fellowship (2000) Immunology of Diabetes Society Junior Investigator Award (1998) Mentoring: Dr. Redondo mentors fellows and students in projects like COVID-19 and Diabetes and Racial Differences in Insulin Pump Uptake , with grants from NIH , Medtronic , and Hemsley Charitable Trust .

• Type 1 Diabetes
• Genetics of Autoimmune Diseases
• Diabetes Heterogeneity
• +3 more

Dr. Channakeshava S. Umeshappa is a faculty member in the Department of Microbiology & Immunology and Department of Pediatrics at Dalhousie University, Canada . He holds a PhD in Immunology from the University of Saskatchewan and completed postdoctoral training at the University of Calgary. Education : DVM (Karnataka Veterinary Animal and Fisheries Sciences University, India), MVSc (Indian Veterinary Research Institute, India), PhD (University of Saskatchewan, Canada) Research Interests : Dr. Umeshappa’s program focuses on immunoregulation in chronic diseases , particularly autoimmunity and cancer. His lab employs genetically modified murine models , omics , synthetic biology , flow cytometry , and imaging to develop immunotherapies. His work emphasizes interdisciplinary collaboration with clinicians and scientists. Article Trends : Recent publications highlight nanomedicine applications in autoimmune liver disease (e.g., peptide-MHC nanomedicines, invariant NKT cell reprogramming) and cancer therapy (e.g., laser-responsive nanoparticles, tumor-to-lymph gels). Studies span immuno-informatics , cell signaling , and clinical outcomes analysis.

• Human Immunology
• Inflammation
• Autoimmunity
• +3 more

Emmanuel Stamatakis is a Professor of Physical Activity, Lifestyle, and Population Health at the University of Sydney's School of Health Sciences (Faculty of Medicine and Health). He holds NHMRC Leadership Fellowships (2021-2025 and 2026-2030) and leads the Charles Perkins Centre's Physical Activity & Exercise Theme. His research focuses on lifestyle behaviors' impacts on cardiometabolic conditions, cancer, and cardiovascular health, using large-scale cohort studies and wearable device data. Key roles include directing the Mackenzie Wearables Research Hub and co-chairing WHO's Physical Activity Guidelines Development Group. Education: PhD from University of Bristol (2003), post-doctoral training at University College London. He leads the ProPASS consortium, involving 45 cohorts with wearable data. Over 460 peer-reviewed publications, including Clarivate's Highly Cited list since 2019. Research interests integrate physical activity, sedentary behavior, and sleep analytics with clinical outcomes. Current projects explore wearables-based measurement innovations, SPAN (sleep-physical activity-nutrition) synergies, and intervention designs for GLP-1 receptor agonist users. Recent articles emphasize VILPA (vigorous intermittent lifestyle physical activity) benefits, sleep-cardiovascular links, and multimodal lifestyle optimization. Awards include Australia's Top Researcher in Sports Medicine and multiple NHMRC grants. Supervises PhD projects on physical activity measurement and intervention design. Active in 50+ peer-reviewed journals and national/international funding bodies.

• Physical Activity Epidemiology
• Public Health
• Cardiometabolic Health
• +4 more

Yang Luo is a Kennedy Trust Senior Research Fellow in Data Science at the University of Oxford's Kennedy Institute of Rheumatology. His research bridges statistical genomics and computational immunology to unravel genetic contributions to immune-mediated traits, with a focus on the major histocompatibility complex (MHC) region. His work leverages large biobank datasets (UK Biobank, Biobank Japan), gene expression resources (GTEx), and proteomic data to decode molecular mechanisms linking genetic variation to disease risk. Specific interests include tuberculosis genetics, multi-ancestry polygenic risk scores, and single-cell eQTL modeling. Recent publications highlight expertise in HLA association studies, evolutionary immunogenetics, and disease-specific cell state dynamics. Key contributions include constructing a global HLA haplotype panel and developing novel statistical methods for admixed population genetics. Scientific Awards: Kennedy Trust Senior Research Fellow in Data Science His lab integrates computational and experimental approaches to translate genetic findings into clinical applications for immune disorders.

• Statistical Genomics
• Computational Immunology
• Human Genetics
• +2 more